These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 18155613)

  • 1. The exploration of rotenone as a toxin for inducing Parkinson's disease in rats, for application in BBB transport and PK-PD experiments.
    Ravenstijn PG; Merlini M; Hameetman M; Murray TK; Ward MA; Lewis H; Ball G; Mottart C; de Ville de Goyet C; Lemarchand T; van Belle K; O'Neill MJ; Danhof M; de Lange EC
    J Pharmacol Toxicol Methods; 2008; 57(2):114-30. PubMed ID: 18155613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The behavioural and neuropathological impact of intranigral AAV-α-synuclein is exacerbated by systemic infusion of the Parkinson's disease-associated pesticide, rotenone, in rats.
    Mulcahy P; O'Doherty A; Paucard A; O'Brien T; Kirik D; Dowd E
    Behav Brain Res; 2013 Apr; 243():6-15. PubMed ID: 23295396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rotenone, deguelin, their metabolites, and the rat model of Parkinson's disease.
    Caboni P; Sherer TB; Zhang N; Taylor G; Na HM; Greenamyre JT; Casida JE
    Chem Res Toxicol; 2004 Nov; 17(11):1540-8. PubMed ID: 15540952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progressive loss of dopaminergic neurons induced by unilateral rotenone infusion into the medial forebrain bundle.
    Norazit A; Meedeniya AC; Nguyen MN; Mackay-Sim A
    Brain Res; 2010 Nov; 1360():119-29. PubMed ID: 20807515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-dependent loss of motor function after unilateral medial forebrain bundle rotenone lesion in rats: a cautionary note.
    Klein A; Gidyk DC; Shriner AM; Colwell KL; Tatton NA; Tatton WG; Metz GA
    Behav Brain Res; 2011 Sep; 222(1):33-42. PubMed ID: 21419806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone.
    Fleming SM; Zhu C; Fernagut PO; Mehta A; DiCarlo CD; Seaman RL; Chesselet MF
    Exp Neurol; 2004 Jun; 187(2):418-29. PubMed ID: 15144868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular pathology in male Lewis rats following short-term, low-dose rotenone administration.
    Allen AL; Luo C; Montgomery DL; Rajput AH; Robinson CA; Rajput A
    Vet Pathol; 2009 Jul; 46(4):776-82. PubMed ID: 19276049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Behavioral differences in a rotenone-induced hemiparkinsonian rat model developed following intranigral or median forebrain bundle infusion.
    Sindhu KM; Saravanan KS; Mohanakumar KP
    Brain Res; 2005 Jul; 1051(1-2):25-34. PubMed ID: 15992782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sleep disturbances in the rotenone animal model of Parkinson disease.
    García-García F; Ponce S; Brown R; Cussen V; Krueger JM
    Brain Res; 2005 May; 1042(2):160-8. PubMed ID: 15854587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The neurobehavioral changes induced by bilateral rotenone lesion in medial forebrain bundle of rats are reversed by L-DOPA.
    Alam M; Mayerhofer A; Schmidt WJ
    Behav Brain Res; 2004 May; 151(1-2):117-24. PubMed ID: 15084427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential pattern of motor impairments in neurotoxic, environmental and inflammation-driven rat models of Parkinson's disease.
    Naughton C; Moriarty N; Feehan J; O'Toole D; Dowd E
    Behav Brain Res; 2016 Jan; 296():451-458. PubMed ID: 26393432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Valproic acid is neuroprotective in the rotenone rat model of Parkinson's disease: involvement of alpha-synuclein.
    Monti B; Gatta V; Piretti F; Raffaelli SS; Virgili M; Contestabile A
    Neurotox Res; 2010 Feb; 17(2):130-41. PubMed ID: 19626387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alpha-synuclein and tyrosine hydroxylase expression in acute rotenone toxicity.
    Luo C; Rajput AH; Akhtar S; Rajput A
    Int J Mol Med; 2007 Mar; 19(3):517-21. PubMed ID: 17273802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delivery of Dual Drug Loaded Lipid Based Nanoparticles across the Blood-Brain Barrier Impart Enhanced Neuroprotection in a Rotenone Induced Mouse Model of Parkinson's Disease.
    Kundu P; Das M; Tripathy K; Sahoo SK
    ACS Chem Neurosci; 2016 Dec; 7(12):1658-1670. PubMed ID: 27642670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute intranigral infusion of rotenone in rats causes progressive biochemical lesions in the striatum similar to Parkinson's disease.
    Saravanan KS; Sindhu KM; Mohanakumar KP
    Brain Res; 2005 Jul; 1049(2):147-55. PubMed ID: 15936733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rats with unilateral median forebrain bundle, but not striatal or nigral, lesions by the neurotoxins MPP+ or rotenone display differential sensitivity to amphetamine and apomorphine.
    Sindhu KM; Banerjee R; Senthilkumar KS; Saravanan KS; Raju BC; Rao JM; Mohanakumar KP
    Pharmacol Biochem Behav; 2006 Jun; 84(2):321-9. PubMed ID: 16820197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sesamol and naringenin reverse the effect of rotenone-induced PD rat model.
    Sonia Angeline M; Sarkar A; Anand K; Ambasta RK; Kumar P
    Neuroscience; 2013 Dec; 254():379-94. PubMed ID: 24070629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rotenone induces non-specific central nervous system and systemic toxicity.
    Lapointe N; St-Hilaire M; Martinoli MG; Blanchet J; Gould P; Rouillard C; Cicchetti F
    FASEB J; 2004 Apr; 18(6):717-9. PubMed ID: 14766796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of pioglitazone and retinoic acid in a rotenone model of Parkinson's disease.
    Ulusoy GK; Celik T; Kayir H; Gürsoy M; Isik AT; Uzbay TI
    Brain Res Bull; 2011 Jul; 85(6):380-4. PubMed ID: 21600965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and characterisation of a novel rat model of Parkinson's disease induced by sequential intranigral administration of AAV-α-synuclein and the pesticide, rotenone.
    Mulcahy P; O'Doherty A; Paucard A; O'Brien T; Kirik D; Dowd E
    Neuroscience; 2012 Feb; 203():170-9. PubMed ID: 22198020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.